More Articles


The Consumer Revolution

Hugh Gosling, (Feb 28, 2017)

As industry truly starts to listen and react to the voices of the people who take its medicines, a more nuanced, insightful picture is emerging about what patients want from pharma and its medicines

Driving Change: Focusing on the Long-Term

Nicola Davies, (Feb 23, 2017)

Do you know how the industry will look in 15 or 20 years, and are you prepared for that future?
Market Access

Face Value

Danielle Barron, (Feb 21, 2017)

With oncology drug prices under intense and growing scrutiny, how are companies proving the value of their medicines?
Market Access

Strength in Numbers

Danielle Barron, (Feb 20, 2017)

R&D innovation is being accelerated through the nurturing of a ground breaking public-private relationship
Market Access

Access All Areas

Deirdre Coleman, (Feb 15, 2017)

Numerous barriers impede the full realization of benefit from Real World Evidence

One Giant Leap for Medical Affairs

Deirdre Coleman, (Feb 14, 2017)

Pharma’s engine of growth lies firmly within Medical Affairs and its ability to partner effectively with other functions.
Market Access

The Price of Everything and the Value of Nothing

Hugh Gosling, (Feb 9, 2017)

What is value and how do we prove it? Economist Dr Jason Shafrin talks prices, politics and the problem of monopolies.

The Real Emotional Sell

Pamela Walker, (Feb 7, 2017)

What are the three key elements that any rep can leverage for a more compelling sell?

Customer Experience: Through Thick and Thin

Hugh Gosling, (Jan 26, 2017)

Enhancing customer experience to improve loyalty could be pharma’s next big step forward

The Art of Mastering Adaptive Engagement

Deirdre Coleman, (Jan 25, 2017)

The age of consumer empowerment is in full force and the industry must respond and adapt to customer engagement.